全文获取类型
收费全文 | 3135篇 |
免费 | 247篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 106篇 |
妇产科学 | 55篇 |
基础医学 | 467篇 |
口腔科学 | 57篇 |
临床医学 | 347篇 |
内科学 | 744篇 |
皮肤病学 | 16篇 |
神经病学 | 294篇 |
特种医学 | 100篇 |
外科学 | 319篇 |
综合类 | 24篇 |
一般理论 | 1篇 |
预防医学 | 227篇 |
眼科学 | 45篇 |
药学 | 238篇 |
中国医学 | 6篇 |
肿瘤学 | 326篇 |
出版年
2023年 | 22篇 |
2022年 | 37篇 |
2021年 | 92篇 |
2020年 | 54篇 |
2019年 | 94篇 |
2018年 | 74篇 |
2017年 | 47篇 |
2016年 | 72篇 |
2015年 | 85篇 |
2014年 | 119篇 |
2013年 | 149篇 |
2012年 | 275篇 |
2011年 | 251篇 |
2010年 | 135篇 |
2009年 | 121篇 |
2008年 | 180篇 |
2007年 | 215篇 |
2006年 | 192篇 |
2005年 | 228篇 |
2004年 | 173篇 |
2003年 | 188篇 |
2002年 | 145篇 |
2001年 | 36篇 |
2000年 | 33篇 |
1999年 | 36篇 |
1998年 | 46篇 |
1997年 | 31篇 |
1996年 | 22篇 |
1995年 | 19篇 |
1994年 | 22篇 |
1993年 | 16篇 |
1992年 | 17篇 |
1991年 | 12篇 |
1990年 | 14篇 |
1989年 | 11篇 |
1987年 | 8篇 |
1986年 | 6篇 |
1985年 | 10篇 |
1984年 | 6篇 |
1983年 | 9篇 |
1982年 | 7篇 |
1980年 | 6篇 |
1979年 | 7篇 |
1978年 | 6篇 |
1977年 | 5篇 |
1975年 | 6篇 |
1973年 | 5篇 |
1972年 | 4篇 |
1970年 | 4篇 |
1968年 | 4篇 |
排序方式: 共有3390条查询结果,搜索用时 15 毫秒
81.
82.
Morgan GJ Davies FE Gregory WM Szubert AJ Bell SE Drayson MT Owen RG Ashcroft AJ Jackson GH Child JA;National Cancer Research Institute Haematological Oncology Clinical Studies Group 《Blood》2012,119(23):5374-5383
The Medical Research Council Myeloma IX Trial (ISRCTNG8454111) examined traditional and thalidomide-based induction and maintenance regimens and IV zoledronic acid (ZOL) and oral clodronate (CLO) in 1960 patients with newly diagnosed multiple myeloma. Overall survival (OS) and skeletal-related event (SRE) data have been reported for the overall trial population. The present analysis investigated optimal therapy regimens for different patient populations in Myeloma IX. Patients were assigned to intensive or nonintensive treatment pathways and randomized to induction cyclophosphamide, vincristine, doxorubicin, and dexamethasone (CVAD) versus cyclophosphamide, thalidomide, and dexamethasone (CTD; intensive) or melphalan and prednisolone versus attenuated oral CTD (CTDa; nonintensive). Patients were also randomized to ZOL or CLO. In the nonintensive pathway, CTDa produced better responses and lower SRE rates than melphalan and prednisolone. ZOL improved OS compared with CLO independently of sex, stage, or myeloma subtype, most profoundly in patients with baseline bone disease or other SREs. In patients treated for ≥ 2 years, ZOL improved OS compared with CLO from randomization (median not reached for either; P = .02) and also from first on-study disease progression (median, 34 months for ZOL vs 27 months for CLO; P = .03). Thalidomide-containing regimens had better efficacy than traditional regimens, and ZOL demonstrated greater benefits than CLO. 相似文献
83.
Dimopoulos MA Richardson PG Brandenburg N Yu Z Weber DM Niesvizky R Morgan GJ 《Blood》2012,119(12):2764-2767
In a retrospective pooled analysis of 11 clinical trials of lenalidomide-based therapy for relapsed/refractory multiple myeloma (MM; N = 3846), the overall incidence rate (IR, events per 100 patient-years) of second primary malignancies (SPMs) was 3.62. IR of invasive (hematologic and solid tumor) SPMs was 2.08, consistent with the background incidence of developing cancer. In a separate analysis of pooled data from pivotal phase 3 trials of relapsed or refractory MM (N = 703), the overall IR of SPMs was 3.98 (95% confidence interval [CI], 2.51-6.31) with lenalidomide/dexamethasone and 1.38 (95% CI, 0.44-4.27) with placebo/dexamethasone; IRs of nonmelanoma skin cancers were 2.40 (95% CI, 1.33-4.33) and 0.91 (95% CI, 0.23-3.66), respectively; IRs of invasive SPMs were 1.71 (95% CI, 0.86-3.43) and 0.91 (95% CI, 0.23-3.66), respectively. The risk of SPMs must be taken into account before initiating lenalidomide treatment. In the context of the observed survival benefit in relapsed or refractory MM patients, the benefit/risk profile of lenalidomide/dexamethasone remains positive. 相似文献
84.
85.
86.
87.
88.
Graham H. Jackson Faith E. Davies Charlotte Pawlyn David A. Cairns Alina Striha Corinne Collett Anna Waterhouse John R. Jones Bhuvan Kishore Mamta Garg Cathy D. Williams Kamaraj Karunanithi Jindriska Lindsay David Allotey Salim Shafeek Matthew W. Jenner Gordon Cook Nigel H. Russell Martin F. Kaiser Mark T. Drayson Roger G. Owen Walter M. Gregory Gareth J. Morgan 《Haematologica》2021,106(7):1957
The optimal way to use immunomodulatory drugs as components of induction and maintenance therapy for multiple myeloma is unresolved. We addressed this question in a large phase III randomized trial, Myeloma XI. Patients with newly diagnosed multiple myeloma (n=2,042) were randomized to induction therapy with cyclophosphamide, thalidomide, and dexamethasone (CTD) or cyclophosphamide, lenalidomide, and dexamethasone (CRD). Additional intensification therapy with cyclophosphamide, bortezomib, and dexamethasone (CVD) was administered before autologous stem-cell transplantation to patients with a suboptimal response to induction therapy using a response-adapted approach. After receiving high-dose melphalan with autologous stem cell transplantation, eligible patients were further randomized to receive either lenalidomide alone or observation alone. Co-primary endpoints were progression-free survival (PFS) and overall survival (OS). The CRD regimen was associated with significantly longer PFS (median: 36 vs. 33 months; hazard ratio [HR], 0.85; 95% confidence interval [CI]: 0.75-0.96; P=0.0116) and OS (3-year OS: 82.9% vs. 77.0%; HR, 0.77; 95% CI: 0.63-0.93; P=0.0072) compared with CTD. The PFS and OS results favored CRD over CTD across all subgroups, including patients with International Staging System stage III disease (HR for PFS, 0.73; 95% CI: 0.58-0.93; HR for OS, 0.78; 95% CI: 0.56-1.09), high-risk cytogenetics (HR for PFS, 0.60; 95% CI: 0.43-0.84; HR for OS, 0.70; 95% CI: 0.42-1.15) and ultra-high-risk cytogenetics (HR for PFS, 0.67; 95% CI: 0.41-1.11; HR for OS, 0.65; 95% CI: 0.34-1.25). Among patients randomized to lenalidomide maintenance (n=451) or observation (n=377), maintenance therapy improved PFS (median: 50 vs. 28 months; HR, 0.47; 95% CI: 0.37-0.60; P<0.0001). Optimal results for PFS and OS were achieved in the patients who received CRD induction and lenalidomide maintenance. The trial was registered with the EU Clinical Trials Register (EudraCT 2009-010956-93) and ISRCTN49407852. 相似文献
89.
Ben Caplin Kristin Veighey Arundathi Mahenderan Miriam Manook Joanne Henry Dorothea Nitsch Mark Harber Peter Dupont David C. Wheeler Gareth Jones Bimbi Fernando Alexander J. Howie Peter Veitch 《Clinical transplantation》2013,27(6):E669-E678
The amount of irreversible injury on renal allograft biopsy predicts function, but little is known about the early evolution of this damage. In a single‐center cohort, we examined the relationship between donor‐, recipient‐, and transplantation‐associated factors and change in a morphometric index of chronic damage (ICD) between protocol biopsies performed at implantation and at 2–3 months. We then investigated whether early delta ICD predicted subsequent biochemical outcomes. We found little evidence to support differences between the study group, who had undergone serial biopsies, and a contemporaneous control group, who had not. In allografts with serial biopsies (n = 162), there was an increase in ICD between implantation (median: 2%, IQR:0–8) and 2–3 months post‐transplant (median 8% IQR:4–15; p < 0.0001). Donation from younger or live donors was independently associated with smaller early post‐transplant increases in ICD. There was no evidence for a difference in delta ICD between donation after cardiac death vs. donation after brain death, nor association with length of cold ischemia. After adjustment for GFR at the time of the second biopsy, delta ICD after three months did not predict allograft function at one yr. These findings suggest that graft damage develops shortly after transplantation and reflects donor factors, but does not predict future biochemical outcomes. 相似文献
90.